Navigation Links
Observational Studies Assess the Potential Impact of Limiting Erythropoiesis-Stimulating Agent Availability on Frequency of Blood Transfusions
Date:5/30/2008

CHICAGO, May 30 /PRNewswire/ -- Data from three observational studies reported at the American Society of Clinical Oncology (ASCO) Annual Meeting evaluated transfusion-related outcomes in cancer chemotherapy patients with various hemoglobin (Hb) levels prior to or during administration of erythropoiesis-stimulating agents (ESAs).

Two analyses were conducted using observational data from the Dosing and Outcomes Study of Erythropoiesis-Stimulating Therapies (DOSE) Registry. The first study (Larholt et al., abstract number 6637) reported that lower mean Hb levels achieved during ESA therapy were associated with increased transfusion requirements in cancer patients receiving chemotherapy. Another study of oncology patients who initiated ESA therapy at different baseline Hb levels (Burton et al., publication number 20637) concluded that blood utilization was greater when ESA therapy was initiated in patients who had baseline Hb of less than 10 grams per deciliter of blood (g/dL) compared with patients who received ESA therapy with a baseline Hb between 10 and 11 g/dL.

The third study (Gilmore, et al., abstract number 6548) examined hematologic outcomes in ESA-treated cancer chemotherapy patients with chemotherapy-induced anemia before and after implementation of the Centers for Medicare and Medicaid Services (CMS) National Coverage Determination (NCD) for ESAs. The results found lower Hb values and higher transfusion rates in patients covered by Medicare following adoption of the NCD guidelines for reimbursement for ESA therapies.

"As ESA coverage policies have become more restrictive, these findings are important in helping stakeholders understand the potential impact on transfusion patterns. The data demonstrated that when patients achieved lower mean hemoglobin levels during ESA therapy for chemotherapy-induced anemia, the need for transfusions increased," said Kay Larholt, Sc.D., Vice President, Biometrics, at Abt Bio-Pharma Solutions, Inc
'/>"/>

SOURCE Ortho Biotech Products, L.P.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Observational Data Show Transfusion Patterns in Chemotherapy-Induced Anemia Patients Receiving Erythropoiesis-Stimulating Agents
2. Two DOXIL(R) Studies to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
3. Genmab Announces Updates on Phase III Cancer Studies
4. Nearly 60 New Studies of Oral Xeloda(R) (capecitabine) Featured at the 44th American Society of Clinical Oncology Annual Meeting
5. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
6. Cryoablation Is Focus of 17 Clinical Studies at American Urological Association Annual Meeting
7. Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies
8. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
9. Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer
10. New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C)
11. N30 Pharma Announces Completion of Phase 1 Clinical Studies With N30-201
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... 2015  Shares of Celladon Corp. (NASDAQ: CLDN ... the announcement of poor drug trial results of the phase ... agent, MYDICAR.  The selloff may be warranted or it ... bargain basement prices. An analyst report update ... pipeline, financial review, analyst summary, valuation, and recommendation can ...
(Date:4/28/2015)... Israel , April 28, 2015 ... in its sixth funding cycle for U.S.- Israel ... and Energy Efficiency. To be considered, a project ... between a company and a university/research institution (one from the ... proposal should have significant commercial potential and the project outcome ...
(Date:4/27/2015)... Techpool Bio-Pharma Co has experienced tremendous changes in ... chief executive officer, transforming from a traditional private Chinese company ... took office in 2011, he was the senior executive ... and Eisai, with more than 20 years successful management experience ... Asia-Pacific region. "I chose Techpool ...
Breaking Medicine Technology:Examining what's Left after MYDICAR Drug Trial Ends In Failure; Celladon Corp. Analyst Report Issued by BrokerBank Securities, Inc. 2Opportunities for Funding U.S.-Israel Cooperation for Renewable Energy and Efficiency 2Techpool Transforms Into International Player 2Techpool Transforms Into International Player 3
... 9, 2011 NeurogesX, Inc. (Nasdaq: NGSX ... novel pain management therapies, today announced it will hold ... p.m. ET (1:30 p.m. PT) to provide an update ... patch for the management of neuropathic pain associated with ...
... Misonix, Inc. (Nasdaq: MSON ), ... markets innovative, therapeutic, ultrasonic products worldwide for wound ... surgical and medical applications, today reported financial results ... ending December 31, 2010.  Michael A. McManus Jr., ...
Cached Medicine Technology:NeurogesX to Provide Qutenza® Launch Update 2NeurogesX to Provide Qutenza® Launch Update 3NeurogesX to Provide Qutenza® Launch Update 4Misonix Reports Second Quarter and Six Months Fiscal 2011 Financial Results 2Misonix Reports Second Quarter and Six Months Fiscal 2011 Financial Results 3Misonix Reports Second Quarter and Six Months Fiscal 2011 Financial Results 4Misonix Reports Second Quarter and Six Months Fiscal 2011 Financial Results 5Misonix Reports Second Quarter and Six Months Fiscal 2011 Financial Results 6
(Date:4/28/2015)... New and more complex medicines ... manufacturers, payers, pharmacists and patients. Now Specialty Pharmacy ... partnering with the National Association of Specialty Pharmacy ... to this developing field to better equip pharmacy ... , “This partnership creates a powerful platform for ...
(Date:4/28/2015)... 28, 2015 Celebrating women has become a ... be the third year that all things mom and female ... Hands On is offering some great specials Special ... of the year could there be to focus on woman," ... pampering and this is a terrific time for it. And ...
(Date:4/28/2015)... 28, 2015 SeniorCare.com has published the ... the reality problem Americans have regarding aging and long-term ... long-term care services as they age, 63% of Americans ... , In the report, Carol Marak of SeniorCare.com interviewed ... American Health Care Association and The Scan Foundation. The ...
(Date:4/28/2015)... Once considered an unproven alternative to HID lighting, the ... storm with perfectly tailored light spectrums in an ideal, low ... than half of every SuperCloset and SuperRoom sold are now ... is gone and LED Grow Lights are here to stay. ... their first hand experience using the new LED Grow lights ...
(Date:4/28/2015)... The west coast, south, east coast, ... areas that healthcare professionals searched for jobs through the ... of March 2015. Data was released by the ... jobs , physical therapy jobs , and other ... health fields. , States with the most ...
Breaking Medicine News(10 mins):Health News:Specialty Pharmacy Times Partners with National Association of Specialty Pharmacy to Improve Care for Patients 2Health News:Specialty Pharmacy Times Partners with National Association of Specialty Pharmacy to Improve Care for Patients 3Health News:Specialty Pharmacy Times Partners with National Association of Specialty Pharmacy to Improve Care for Patients 4Health News:Commack Massage Therapy and Wellness Day Spa Dedicates Time To Celebrate Women 2Health News:SeniorCare.com Report: America Has a Major Misconception on Aging 2Health News:SuperCloset Reports Surge in KIND LED Grow Light Sales, Saving Indoor Growing Enthusiasts up to 40% on their Power Usage. 2Health News:Hot States for Medical Careers: Healthcare Staffing Agency Aureus Medical Releases Online Search Results 2
... genetic factors and drug abuse saying that genetic tendencies play ... ,Dr. Kenneth S. Kendler, who has led the ... the importance of genetic factors in a culture/country (Norway) with ... that in such countries, social rather than genetics factors should ...
... When the body's arteries, veins and capillaries become diseased, ... the possibility of stroke and heart attack.// Dennis Gable, ... Baylor Regional Medical Center at Plano, provides information about ... ,Varicose veins: ,Varicose veins are large, twisted, swollen ...
... person dying of coronary heart disease can be predicted by ... venules in the eyes. ,Arterioles and venules are ... reflects the general state of the smaller blood vessels in ... of the study, 78 women (just over 4%) and 114 ...
... be a wake up call to get the duvets washed and ... their duvets even in six months, and these could// be the ... ,A survey conducted in many households revealed that two ... months. The dust mites and filth are potential health hazards ...
... have said one therapeutic dose of radiation resulted in mice ... ,Research in US have indicated, in a study ... Physiology that mice that has received a single therapeutic dose ... of radiation received by human cancer patients lost as much ...
... NHS has launched National Transplant Week to raise awareness of ... take place and the number of people// awaiting transplants. ... population in Britain has joined the Organ Donor Register. In ... on transplant lists, only 2,200 actually operations took place. ...
Cached Medicine News:Health News:Vascular Disease 101: Discovering and Treating Common Diseases of the Veins 2Health News:National Transplant Week to Raise Need for Organ Donation 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: